Concurrent Mantle Cell Lymphoma and Paraneoplastic Membranous Nephropathy

IF 4.1 Q1 UROLOGY & NEPHROLOGY
Kidney Medicine Pub Date : 2026-07-01 Epub Date: 2026-04-27 DOI:10.1016/j.xkme.2026.101372
Daoyuan Lv, Ping Sun, Yuanyuan Li, Tingting Liu, Fan Ye, Yafen Yu, Tiekun Li, Aining Liu
{"title":"Concurrent Mantle Cell Lymphoma and Paraneoplastic Membranous Nephropathy","authors":"Daoyuan Lv,&nbsp;Ping Sun,&nbsp;Yuanyuan Li,&nbsp;Tingting Liu,&nbsp;Fan Ye,&nbsp;Yafen Yu,&nbsp;Tiekun Li,&nbsp;Aining Liu","doi":"10.1016/j.xkme.2026.101372","DOIUrl":null,"url":null,"abstract":"<div><div>We report a rare case of synchronous stage IV mantle cell lymphoma (MCL) and paraneoplastic membranous nephropathy (MN) in a 48-year-old man. The patient presented with a nasopharyngeal mass; biopsy confirmed cyclin D1-positive MCL harboring the <em>CCND1::IGH</em> rearrangement, along with nephrotic syndrome. Kidney biopsy revealed MN with IgG1/IgG3-dominant glomerular deposits but was negative for PLA2R, THSD7A, and NELL-1 antigens in both renal and tumor tissues, with corresponding serum antibodies undetectable. After lymphoma-directed therapy alone (R-CHOP/R-DHAP induction, autologous hematopoietic stem cell transplantation consolidation, and extended rituximab maintenance), both conditions achieved sustained remission. Complete remission was confirmed per the Lugano 2014 criteria, and nephrotic syndrome resolved, with proteinuria decreasing from 7.38 to 0.29 g/24 hours and serum albumin improving from 26.2 to 35.5 g/L with preserved kidney function. Both MCL and MN remained in remission for &gt;2 years. This case highlights MCL-associated MN as a PLA2R/THSD7A/NELL-1 triple-negative entity where antineoplastic therapy alone induces renal remission, demonstrating both the paraneoplastic mechanism and the feasibility of intensive lymphoma treatment, including transplantation without renal compromise.</div></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"8 7","pages":"Article 101372"},"PeriodicalIF":4.1000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312128/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590059526001330","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We report a rare case of synchronous stage IV mantle cell lymphoma (MCL) and paraneoplastic membranous nephropathy (MN) in a 48-year-old man. The patient presented with a nasopharyngeal mass; biopsy confirmed cyclin D1-positive MCL harboring the CCND1::IGH rearrangement, along with nephrotic syndrome. Kidney biopsy revealed MN with IgG1/IgG3-dominant glomerular deposits but was negative for PLA2R, THSD7A, and NELL-1 antigens in both renal and tumor tissues, with corresponding serum antibodies undetectable. After lymphoma-directed therapy alone (R-CHOP/R-DHAP induction, autologous hematopoietic stem cell transplantation consolidation, and extended rituximab maintenance), both conditions achieved sustained remission. Complete remission was confirmed per the Lugano 2014 criteria, and nephrotic syndrome resolved, with proteinuria decreasing from 7.38 to 0.29 g/24 hours and serum albumin improving from 26.2 to 35.5 g/L with preserved kidney function. Both MCL and MN remained in remission for >2 years. This case highlights MCL-associated MN as a PLA2R/THSD7A/NELL-1 triple-negative entity where antineoplastic therapy alone induces renal remission, demonstrating both the paraneoplastic mechanism and the feasibility of intensive lymphoma treatment, including transplantation without renal compromise.
并发套细胞淋巴瘤和副肿瘤膜性肾病。
我们报告一例罕见的同步IV期套细胞淋巴瘤(MCL)和副瘤膜性肾病(MN)在一个48岁的男性。患者表现为鼻咽肿块;活检证实细胞周期蛋白d1阳性MCL伴有CCND1::IGH重排,并伴有肾病综合征。肾活检显示MN肾小球沉积以IgG1/ igg3为主,但在肾脏和肿瘤组织中PLA2R、THSD7A和nell1抗原均为阴性,相应的血清抗体检测不到。经过单独的淋巴瘤定向治疗(R-CHOP/R-DHAP诱导,自体造血干细胞移植巩固,延长利妥昔单抗维持),这两种情况都实现了持续缓解。根据Lugano 2014标准,患者完全缓解,肾病综合征得到缓解,蛋白尿从7.38 g/24小时降至0.29 g/24小时,血清白蛋白从26.2 g/L降至35.5 g/L,肾功能得以保留。MCL和MN的缓解期均为50年。该病例强调了mcl相关MN作为PLA2R/THSD7A/NELL-1三阴性实体,单独抗肿瘤治疗可诱导肾脏缓解,证明了副肿瘤机制和强化淋巴瘤治疗的可行性,包括不损害肾脏的移植。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney Medicine
Kidney Medicine Medicine-Internal Medicine
CiteScore
4.80
自引率
5.10%
发文量
176
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书